Veena John, MD

Assistant Investigator, The Karches Center for Oncology Research,
The Feinstein Institute for Medical Research

Assistant Professor of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Phone: (516) 734-8876
Email: vjohn@northwell.edu

About the Investigator

Dr. Veena John is a board certified Hematologist/Oncologist. She has worked for Northwell Health for the last 15 years and specializes in Gynecologic Oncology and breast cancer. She is also the co-chair for the CSSRC. Dr. John is the principal investigator for Gynecologic Oncology Group clinical trials and multiple pharma studies. She cochairs the Gynecologic Cancer Center of Excellence and she is the chair for gynecologic disease team. She is responsible for teaching the fellows and is involved in running the fellows clinic.  She is also involved in the genetics program at Monter Cancer Center.

Research Focus

Dr. Veena John’s main research focus is on Gyn cancer, especially ovarian cancer. She is the principal investigator for multiple phase II and phase III studies. Her main focus is on finding better treatment for ovarian cancer and also prevention and early detection.

Education

North Shore University Hospital, Manhasset, NY
Degree: Fellowship
2002
Field of Study: Hematology/Oncology

Flushing Hospital Medical Center, Queens. NY
Degree: Residency
1999
Field of Study: Internal Medicine

Christian Medical College, Ludhian, India
Degree: MBBS
1992

Publications
  1. Myra F Barginear, Veena John, and Daniel R Budman “Trastuzumab-DM1: A Clinical Update of the Novel Antibody-Drug Conjugate for HER2-Overexpressing Breast Cancer.” Mol Med. 2013 Jan 22; 18:1473-9. doi: 10.2119/molmed.2012.00302.
  2. Veena John; Sandeep Mashru; Stuart M Lichtman “Pharmacological factors influencing anticancer drug selection in the elderly.” Drugs & aging 2003;20(10):737-59.
  3. Greben, Craig R. MD*; Goldstein, Greg E. MD*; Lovecchio, John MD†; John, Veena MD‡; Putterman, Daniel MD*; Caplin, Drew MD*; Gandras, Eric J. MD*: “Percutaneous Insertion of Peritoneal Ports” International Journal of Gynecological Cancer: February 2012 – Volume 22 – Issue 2 – p 328–331 International Journal of Gynecological Cancer (Impact Factor: 1.94). 11/2011; 22(2):328-31. DOI: 10.1097/IGC.0b013e318234f7a8
  4. Budman DR, Tai J, Calabro A, John V: “The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.” Invest New Drugs. 2011 Dec;29(6):1224-9. doi: 10.1007/s10637-010-9467-6.Epub 2010 Jun 9.

View more at PubMed